HK1142083A1 - Human antibodies that bind human il-12 and methods for producing - Google Patents

Human antibodies that bind human il-12 and methods for producing

Info

Publication number
HK1142083A1
HK1142083A1 HK10108446.1A HK10108446A HK1142083A1 HK 1142083 A1 HK1142083 A1 HK 1142083A1 HK 10108446 A HK10108446 A HK 10108446A HK 1142083 A1 HK1142083 A1 HK 1142083A1
Authority
HK
Hong Kong
Prior art keywords
human
producing
methods
bind
antibodies
Prior art date
Application number
HK10108446.1A
Other languages
English (en)
Inventor
Jochen Salfeld
Michael Roguska
Michael Paskind
Subhashis Banerjee
Daniel E Tracey
Michael White
Zehra Kaymakcalan
Boris Labkovsky
Paul Sakorafas
Stuart Friedrich
Angela Myles
Geertruida M Veldman
Amy Venturini
Nicholas W Warne
Angela Widom
John G Elvin
Alexander R Duncan
Elaine J Derbyshire
Sara Carmen
Stephen Smith
Thor Las Holtet
Fou Sarah L Du
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22425740&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1142083(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of HK1142083A1 publication Critical patent/HK1142083A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
HK10108446.1A 1999-03-25 2010-09-06 Human antibodies that bind human il-12 and methods for producing HK1142083A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12660399P 1999-03-25 1999-03-25

Publications (1)

Publication Number Publication Date
HK1142083A1 true HK1142083A1 (en) 2010-11-26

Family

ID=22425740

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10108446.1A HK1142083A1 (en) 1999-03-25 2010-09-06 Human antibodies that bind human il-12 and methods for producing

Country Status (29)

Country Link
EP (4) EP2168984B1 (fr)
JP (3) JP4841038B2 (fr)
KR (6) KR101222450B1 (fr)
CN (4) CN101066997B (fr)
AR (3) AR043274A1 (fr)
AU (1) AU3921600A (fr)
BG (2) BG66399B1 (fr)
BR (1) BR0009323A (fr)
CA (3) CA2796140A1 (fr)
CY (2) CY1113326T1 (fr)
CZ (1) CZ303725B6 (fr)
DK (1) DK2168984T3 (fr)
ES (1) ES2390849T3 (fr)
HK (1) HK1142083A1 (fr)
HU (1) HUP0200575A3 (fr)
IL (3) IL145134A0 (fr)
LU (1) LU92159I2 (fr)
MX (1) MXPA01009645A (fr)
MY (2) MY145191A (fr)
NO (3) NO334828B1 (fr)
NZ (5) NZ596723A (fr)
PL (2) PL409839A1 (fr)
PT (1) PT2168984E (fr)
SI (1) SI2168984T1 (fr)
SK (1) SK288082B6 (fr)
TR (5) TR200503572T2 (fr)
TW (5) TWI339209B (fr)
WO (1) WO2000056772A1 (fr)
ZA (1) ZA200107774B (fr)

Families Citing this family (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
CA2796140A1 (fr) * 1999-03-25 2000-09-28 Jochen Salfeld Anticorps humains de liaison de l'il-12 humaine et methodes de production connexes
US7883704B2 (en) * 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
TWI335336B (fr) 2000-02-10 2011-01-01 Abbott Gmbh & Co Kg
SK1152003A3 (en) 2000-06-29 2003-07-01 Abbott Lab Dual specificity antibodies and methods of making and using
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
PE20020801A1 (es) 2001-01-05 2002-09-06 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina
NZ532021A (en) 2001-10-04 2008-05-30 Genetics Inst Llc Methods and compositions for modulating interleukin-21 receptor activity
KR100913714B1 (ko) 2001-11-08 2009-08-24 패시트 바이오테크 코포레이션 Ｉｇｇ 항체의 안정한 액상 약학 제형물
EP1494710A4 (fr) * 2002-03-26 2007-03-21 Centocor Inc Proteines derivees de l'immunoglobuline liees au diabete, compositions, methodes et utilisations relatives a ces proteines
AU2003220557A1 (en) * 2002-03-26 2003-10-13 Centocor, Inc. Multiple sclerosis-related immunoglobulin derived proteins, compositions, methods and uses
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
JP5477998B2 (ja) 2002-10-30 2014-04-23 ジェネンテック， インコーポレイテッド Ｉｌ−１７産生の阻害
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
CA2505326A1 (fr) 2002-11-08 2004-05-21 Ablynx N.V. Procede d'administration de polypeptides therapeutiques et polypeptides associes
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
EP1558645B1 (fr) 2002-11-08 2011-07-27 Ablynx N.V. Anticorps a domaine unique stabilises dans une composition pharmaceutique pour inhalation
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
SI3417875T1 (sl) 2003-02-10 2021-01-29 Biogen Ma Inc. Formulacija imunoglobulina in metode za njegovo pripravo
AU2012202845B2 (en) * 2003-02-10 2014-09-04 Biogen Ma Inc. Immunoglobulin formulation and method of preparation thereof
RU2005131852A (ru) 2003-03-14 2006-04-20 Уайт (Us) Антитела против человеческого рецептора il-21 и их применение
KR100825156B1 (ko) 2003-08-13 2008-04-24 화이자 프로덕츠 인코포레이티드 변형된 인간 ｉｇｆ-ｉｒ 항체
FR2859725B1 (fr) 2003-09-16 2006-03-10 Neovacs Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
EP1531162A1 (fr) 2003-11-14 2005-05-18 Heinz Vollmers Anticorps SAM-6, spécifique d'adénocarcinome, et ses utilisations
DE10353175A1 (de) * 2003-11-14 2005-06-16 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper mit fettsenkender Wirkung
RU2386638C2 (ru) * 2004-03-31 2010-04-20 Дженентек, Инк. Гуманизированные анти-тфр-бета-антитела
ME00226B (me) 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
CA2591813A1 (fr) 2004-12-21 2006-06-29 Centocor, Inc. Anticorps anti-il-12, epitopes, compositions, procedes et utilisations associes
HUE042689T2 (hu) 2005-02-08 2019-07-29 Genzyme Corp TGFbéta elleni antitestek
CN101160528A (zh) 2005-02-14 2008-04-09 惠氏公司 Il17-f在诊断和治疗气道炎症中的用途
WO2006088833A2 (fr) 2005-02-14 2006-08-24 Wyeth Anticorps de l'interleukine-17f et d'autres antagonistes de signalisation de l'il-17f et leurs utilisations correspondantes
GT200600148A (es) 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
CN103172738A (zh) * 2005-06-30 2013-06-26 Abbvie公司 Il-12/p40结合蛋白
CN101321783B (zh) 2005-07-18 2015-08-26 安姆根有限公司 人抗-b7rp1中和抗体
EP2500354A3 (fr) 2005-08-19 2012-10-24 Abbott Laboratories Immunoglobuline à double domaine variable et ses utilisations
WO2007024715A2 (fr) 2005-08-19 2007-03-01 Abbott Laboratories Immunoglobuline a deux domaines variables et utilisations de celle-ci
CA2624562A1 (fr) 2005-09-30 2007-04-12 Abbott Gmbh & Co. Kg Domaines de liaison de proteines de la famille proteinique des molecules de guidage repulsif (rgm), fragments fonctionnels de ces domaines et leur utilisation
CA2631195C (fr) 2005-11-30 2016-04-05 Abbott Laboratories Anticorps monoclonaux et utilisation de ceux-ci
CN101432302A (zh) 2005-11-30 2009-05-13 艾博特公司 抗－Aβ球聚体抗体，其抗原结合部分，相应的杂交瘤、核酸、载体、宿主细胞，生产所述抗体的方法，包含所述抗体的组合物，所述抗体的应用以及使用所述抗体的方法
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
KR101544108B1 (ko) 2006-09-08 2015-08-13 애브비 바하마스 리미티드 인터루킨-13 결합 단백질
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8324350B2 (en) 2006-12-29 2012-12-04 Abbott Laboratories Dual-specific IL-1α/IL-1β antibodies
US7776331B1 (en) 2007-01-16 2010-08-17 Abbott Laboratories Methods of treating plaque psoriasis
EP2124952A2 (fr) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Méthode de traitement d'amyloïdoses
CA2681752A1 (fr) * 2007-03-29 2008-10-09 Abbott Laboratories Anticorps anti-1l-12 humains cristallins
US20110014117A1 (en) * 2007-06-28 2011-01-20 Schering Corporation Anti-igf1r
US20090181027A1 (en) * 2007-09-28 2009-07-16 Paul Dal Monte Anti-IL-12/23p40 Antibodies, Epitopes, Formulations, Compositions, Methods and Uses
EP2050764A1 (fr) * 2007-10-15 2009-04-22 sanofi-aventis Nouveau format d'anticorps bispécifique polyvalent
AU2008328785A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
RU2497545C2 (ru) 2008-03-18 2013-11-10 Эбботт Лэборетриз Способ лечения псориаза (варианты)
KR20110014607A (ko) 2008-04-29 2011-02-11 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
CA2721713C (fr) 2008-05-05 2019-07-09 Novimmune Sa Anticorps a reaction croisee anti-il-17a/il-17f et leurs procedes d'utilisation
WO2009136382A2 (fr) 2008-05-09 2009-11-12 Abbott Gmbh & Co. Kg Anticorps contre le récepteur des produits terminaux de glycation avancée (rage) et leurs utilisations
EP3705135A1 (fr) * 2008-05-30 2020-09-09 XBiotech, Inc Il-1 alpha abs et leurs procédés d'utilisation
UY31861A (es) 2008-06-03 2010-01-05 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
MX2010013239A (es) 2008-06-03 2011-02-24 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
RU2559525C2 (ru) 2008-07-08 2015-08-10 Эббви Инк Белки, связывающие простагландин е2, и их применение
MX2010014574A (es) 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
CN104740631B (zh) 2008-10-29 2019-04-16 阿布林克斯公司 单域抗原结合性分子的制剂
EP2346900A1 (fr) 2008-10-29 2011-07-27 Wyeth LLC Procédés de purification de molécules de liaison d'antigène monodomaines
NZ592644A (en) * 2008-11-28 2013-09-27 Abbott Lab Stable antibody compositions and methods for stabilizing same
US8030026B2 (en) * 2009-02-24 2011-10-04 Abbott Laboratories Antibodies to troponin I and methods of use thereof
NZ611324A (en) 2009-03-05 2015-02-27 Abbvie Inc Il-17 binding proteins
MX2011011729A (es) 2009-05-05 2012-04-10 Novimmune Sa Anticuerpo anti il-17f y metodos de uso de los mismos.
PE20121647A1 (es) 2009-08-29 2012-12-31 Abbvie Inc Proteinas terapeuticas de union a dll4
UY32870A (es) 2009-09-01 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
MX2012003138A (es) * 2009-09-14 2012-07-04 Abbott Lab Y Abbott Gmbh & Co Kg Metodos para tratar la psoriasis.
RU2012119756A (ru) 2009-10-15 2013-11-20 Эбботт Лэборетриз Иммуноглобулины с двумя вариабельными доменами и их применение
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
TW201121568A (en) 2009-10-31 2011-07-01 Abbott Lab Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
WO2011051466A1 (fr) 2009-11-02 2011-05-05 Novartis Ag Molécules de liaison anti-idiotypiques à base de fibronectine et leurs utilisations
WO2011070045A1 (fr) 2009-12-08 2011-06-16 Abbott Gmbh & Co. Kg Anticorps monoclonaux contre la protéine rgm a destinés à être utilisés dans le traitement de la dégénérescence de la couche de fibres nerveuses rétiniennes
WO2011071059A1 (fr) 2009-12-09 2011-06-16 国立大学法人大阪大学 Inhibiteur d'activation des lymphocytes t, composition pharmaceutique contenant celui-ci, et procédé de criblage pour une substance inhibant l'activation des lymphocytes t
WO2011109298A2 (fr) 2010-03-02 2011-09-09 Abbott Laboratories Protéines thérapeutiques de liaison à dll4
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
UY33386A (es) 2010-05-14 2011-12-30 Abbott Laboratoires Proteínas de unión a il-1
WO2012006500A2 (fr) 2010-07-08 2012-01-12 Abbott Laboratories Anticorps monoclonaux contre la protéine de capside du virus de l'hépatite c
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
TW201206473A (en) 2010-08-03 2012-02-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
SI3333188T1 (sl) 2010-08-19 2022-04-29 Zoetis Belgium S.A. Protitelesa proti NGF in njihova uporaba
JP2013539364A (ja) 2010-08-26 2013-10-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
MY188828A (en) 2010-09-17 2022-01-06 Takeda Pharmaceuticals Co Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral ph
WO2012088094A2 (fr) 2010-12-21 2012-06-28 Abbott Laboratories Protéines liant l'il-1
JP6009455B2 (ja) 2010-12-21 2016-10-19 アッヴィ・インコーポレイテッド Ｉｌ−１アルファおよびベータ二重特異的二重可変ドメイン免疫グロブリンおよびその使用
JP2014520847A (ja) 2011-07-13 2014-08-25 アッヴィ・インコーポレイテッド 抗ｉｌ−１３抗体を使用して喘息を治療するための方法および組成物
EP2771360A1 (fr) 2011-10-24 2014-09-03 AbbVie Inc. Agents de liaison immunologique dirigés contre la sclérostine
CA2855840C (fr) * 2011-12-14 2023-08-29 AbbVie Deutschland GmbH & Co. KG Composition et methode pour le diagnostic et le traitement de troubles lies au fer
MX356933B (es) 2011-12-14 2018-06-20 Abbvie Deutschland Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
MX2014008101A (es) 2011-12-30 2014-09-25 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-13 y/o il-17.
NZ714482A (en) 2012-01-27 2017-08-25 Abbvie Inc Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
TWI609882B (zh) 2012-05-22 2018-01-01 必治妥美雅史谷比公司 雙特異性抗體及其使用方法
CA2875783C (fr) 2012-06-06 2018-12-11 Zoetis Llc Anticorps anti-ngf caninises et procedes associes
AR091755A1 (es) 2012-07-12 2015-02-25 Abbvie Inc Proteinas de union a il-1
HUE049282T2 (hu) 2012-09-07 2020-09-28 Coherus Biosciences Inc Adalimumab stabil vizes formulációi
TW201811825A (zh) 2012-11-01 2018-04-01 美商艾伯維有限公司 抗-ｖｅｇｆ／ｄｌｌ４雙重可變區域免疫球蛋白及其用途
WO2014100542A1 (fr) 2012-12-21 2014-06-26 Abbvie, Inc. Humanisation d'anticorps à haut rendement
KR102068222B1 (ko) 2013-02-20 2020-01-21 삼성디스플레이 주식회사 증착용 마스크 제조방법
JOP20140087B1 (ar) 2013-03-13 2021-08-17 Amgen Inc بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
MX362075B (es) 2013-03-14 2019-01-07 Abbott Lab Ensayo de combinación de antígeno-anticuerpo del virus de la hepatitis c (vhc) y métodos y composiciones para usarlo.
CA2906407A1 (fr) 2013-03-14 2014-09-18 Abbott Laboratories Antigenes recombinants ns3 de vhc et leurs mutants pour la detection d'anticorps amelioree
JP6739329B2 (ja) 2013-03-14 2020-08-12 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ Ｈｃｖコア脂質結合ドメインモノクローナル抗体
TW201512219A (zh) 2013-03-15 2015-04-01 Abbvie Inc 針對ＩＬ－１β及／或ＩＬ－１７之雙特異性結合蛋白
US9469686B2 (en) 2013-03-15 2016-10-18 Abbott Laboratories Anti-GP73 monoclonal antibodies and methods of obtaining the same
CN103275222B (zh) * 2013-05-15 2014-04-16 中山康方生物医药有限公司 一种阻断白介素12 p40功能的单克隆抗体及其编码基因和应用
EP3003372B1 (fr) 2013-06-07 2019-10-09 Duke University Inhibiteurs du facteur h du complément
KR102400060B1 (ko) 2013-12-26 2022-05-19 미쓰비시 타나베 파마 코퍼레이션 인간 항 il-33 중화 단일클론 항체
EA201790737A1 (ru) * 2014-10-03 2017-08-31 Новартис Аг Комбинированная терапия
MX2017004975A (es) * 2014-10-18 2017-06-30 Pfizer Composiciones de anticuerpos anti-il-7r.
AR102417A1 (es) 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
WO2016094881A2 (fr) 2014-12-11 2016-06-16 Abbvie Inc. Protéines de liaison à lrp-8
SI3303395T1 (sl) 2015-05-29 2020-03-31 Abbvie Inc. Protitelesa proti CD40 in njihove uporabe
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
CN105825196B (zh) * 2016-03-28 2020-01-31 联想(北京)有限公司 一种信息处理方法和电子设备
JP7468992B2 (ja) 2016-03-29 2024-04-16 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ１２及び／又は－２３抗体の増加した間隔投与による乾癬の処置
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
WO2018057955A1 (fr) * 2016-09-23 2018-03-29 Elstar Therapeutics, Inc. Molécules d'anticorps multispécifiques comprenant des chaînes légères lambda et kappa
MX2019003473A (es) 2016-10-03 2019-10-15 Abbott Lab Metodos mejorados para evaluar el estado de ubiquitin carboxi-terminal hidrolasa l1 (uch-l1) en muestras de pacientes.
WO2018175942A1 (fr) 2017-03-23 2018-09-27 Abbott Laboratories Méthodes d'aide au diagnostic et à la détermination de l'étendue d'une lésion cérébrale traumatique chez un sujet humain à l'aide du biomarqueur précoce hydrolase carboxy-terminale d'ubiquitine l1
CA3053409A1 (fr) 2017-04-15 2018-10-18 Abbott Laboratories Procedes d'aide au diagnostic hyperaigu et de determination d'une lesion cerebrale traumatique chez un sujet humain a l'aide de biomarqueurs precoces
BR112019022476A2 (pt) 2017-04-28 2020-05-12 Abbott Laboratories Métodos para o auxílio no diagnóstico e determinação hiperagudos de lesão cerebral traumática usando biomarcadores iniciais em pelo menos duas amostras a partir do mesmo ser humano
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
US10866251B2 (en) 2017-05-25 2020-12-15 Abbott Laboratories Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
BR112019025387A2 (pt) 2017-05-30 2020-07-07 Abbott Laboratories métodos para auxiliar no diagnóstico e avaliação de uma lesão traumática cerebral branda em um indivíduo humano com o uso de troponina cardíaca i e biomarcadores precoces
JP7454945B2 (ja) 2017-07-03 2024-03-25 アボット・ラボラトリーズ 血液中のユビキチンカルボキシ末端ヒドロラーゼｌ１レベルを測定するための、改善された方法
SG11202001786PA (en) 2017-08-31 2020-03-30 Mitsubishi Tanabe Pharma Corp Il-33 antagonist-containing therapeutic agent for endometriosis
TW201922780A (zh) * 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
CN110892266A (zh) 2017-12-09 2020-03-17 雅培实验室 使用gfap和uch-l1的组合辅助诊断和评价人类受试者中创伤性脑损伤的方法
US11022617B2 (en) 2017-12-09 2021-06-01 Abbott Laboratories Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using glial fibrillary acidic protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase L1 (UCH-L1)
CA3085576A1 (fr) * 2017-12-13 2019-06-20 The Research Foundation For The State University Of New York Peptides et autres agents pour traiter la douleur et augmenter la sensibilite a la douleur
RU2020129265A (ru) 2018-03-12 2022-04-12 ЗОИТИС СЕРВИСЕЗ ЭлЭлСи Антитела против ngf и связанные с ними способы
US11578124B2 (en) 2018-05-18 2023-02-14 Janssen Biotech, Inc. Safe and effective method of treating lupus with anti-IL12/IL23 antibody
FI3883606T3 (fi) 2018-09-24 2023-09-07 Janssen Biotech Inc Turvallinen ja tehokas menetelmä haavaisen paksusuolitulehduksen hoitamiseksi anti-il12/il23-vasta-aineella
CN111057719B (zh) * 2018-10-17 2022-11-11 南京大学 一种高效的小鼠骨髓来源巨噬细胞的转染方法及其应用
JP2022534020A (ja) 2019-05-23 2022-07-27 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
CN110204736A (zh) * 2019-06-07 2019-09-06 河南师范大学 一步合成不同形貌Pb-MOF金属有机骨架的方法
CN115397848A (zh) 2020-02-05 2022-11-25 拉利玛生物医药公司 Tat肽结合蛋白及其用途
CN111471655B (zh) * 2020-03-19 2023-07-07 湖州正熙医学检验实验室有限公司 抗人il12/23稳转细胞株及其构建方法和应用
WO2022031804A1 (fr) 2020-08-04 2022-02-10 Abbott Laboratories Méthodes et kits améliorés pour détecter une protéine sars-cov-2 dans un échantillon
WO2022119841A1 (fr) 2020-12-01 2022-06-09 Abbott Laboratories Utilisation d'un ou plusieurs biomarqueurs pour déterminer un traumatisme crânien (tbi) chez un sujet soumis à un balayage de tomodensitométrie assistée par ordinateur de la tête à tbi négatif
WO2023102384A1 (fr) 2021-11-30 2023-06-08 Abbott Laboratories Utilisation d'un ou de plusieurs biomarqueurs pour déterminer un traumatisme crânien (tbi) chez un sujet ayant été soumis à un balayage de tomodensitométrie assistée par ordinateur de la tête ne démontrant par de tbi
WO2022147147A1 (fr) 2020-12-30 2022-07-07 Abbott Laboratories Procédés pour déterminer un antigène sras-cov-2 et anticorps anti-sras-cov-2 dans un échantillon
EP4341699A1 (fr) 2021-05-18 2024-03-27 Abbott Laboratories Procédés d'évaluation d'une lésion cérébrale chez un sujet en pédiatrie
US20240118279A1 (en) 2021-06-14 2024-04-11 Abbott Laboratories Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
CN113321729B (zh) * 2021-07-01 2022-08-30 东大生物技术(苏州)有限公司 一组il-12单克隆抗体及其医药用途
CA3230038A1 (fr) 2021-08-31 2023-03-09 Hongwei Zhang Methodes et systemes de diagnostic de lesion cerebrale
AU2022354059A1 (en) 2021-09-30 2024-03-28 Abbott Laboratories Methods and systems of diagnosing brain injury
CA3240822A1 (fr) 2021-12-17 2023-06-22 Tony Lee Systemes et procedes de determination d'uch-l1, de gfap et d'autres biomarqueurs dans des echantillons de sang
US20230213536A1 (en) 2021-12-28 2023-07-06 Abbott Laboratories Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
WO2023150652A1 (fr) 2022-02-04 2023-08-10 Abbott Laboratories Procédés d'écoulement latéral, dosages et dispositifs de détection de la présence ou de mesure de la quantité d'ubiquitine carboxy-terminal hydrolase l1 et/ou d'une protéine gliofibrillaire acide dans un échantillon
KR20230171660A (ko) 2022-06-14 2023-12-21 오상민 공기 살균 정화기
WO2024006876A1 (fr) 2022-06-29 2024-01-04 Abbott Laboratories Systèmes et analyses magnétiques hors laboratoire pour déterminer une gfap dans des échantillons biologiques
WO2024059708A1 (fr) 2022-09-15 2024-03-21 Abbott Laboratories Biomarqueurs et méthodes de différenciation entre une lésion cérébrale traumatique légère et très légère

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
KR0185192B1 (ko) 1989-10-05 1999-04-01 제임스 더블유. 데이비 신규의 유전자 및 폴리펩티드의 무세포 합성 및 분리
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ　アンティボディー　テクノロジー　リミティド 特異的な結合ペアーの構成員の製造方法
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
JP3672306B2 (ja) 1991-04-10 2005-07-20 ザ スクリップス リサーチ インスティテュート ファージミドを使用するヘテロ二量体受容体ライブラリー
WO1994004679A1 (fr) * 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5734014A (en) * 1992-08-11 1998-03-31 Tsumura & Co. Elafin derivative
US5654168A (en) 1994-07-01 1997-08-05 Basf Aktiengesellschaft Tetracycline-inducible transcriptional activator and tetracycline-regulated transcription units
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
EP0659766A1 (fr) * 1993-11-23 1995-06-28 Schering-Plough Anticorps monoclonaux humains contre des cytokines humains et méthode de fabrication de tels anticorps
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
ATE390933T1 (de) * 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
US5853697A (en) 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
AU4959997A (en) * 1996-11-15 1998-06-10 Kennedy Institute Of Rheumatology, The Suppression of tnf alpha and il-12 in therapy
CA2796140A1 (fr) * 1999-03-25 2000-09-28 Jochen Salfeld Anticorps humains de liaison de l'il-12 humaine et methodes de production connexes
US9601381B2 (en) 2013-12-05 2017-03-21 Stmicroelectronics (Crolles 2) Sas Method for the formation of a finFET device with epitaxially grown source-drain regions having a reduced leakage path

Also Published As

Publication number Publication date
ES2390849T3 (es) 2012-11-19
TWI280980B (en) 2007-05-11
NZ513945A (en) 2001-09-28
TWI365193B (en) 2012-06-01
TR200503572T2 (tr) 2006-04-21
EP1175446A1 (fr) 2002-01-30
KR20140094647A (ko) 2014-07-30
TR200603997T1 (tr) 2010-01-21
TWI339209B (en) 2011-03-21
CN101333256A (zh) 2008-12-31
TW201043639A (en) 2010-12-16
ZA200107774B (en) 2002-12-20
BG66399B1 (bg) 2013-12-31
AR094125A2 (es) 2015-07-15
TW201300412A (zh) 2013-01-01
KR20120091477A (ko) 2012-08-17
TW200738749A (en) 2007-10-16
EP2168984A1 (fr) 2010-03-31
CN101066997B (zh) 2013-03-27
KR20100021669A (ko) 2010-02-25
MXPA01009645A (es) 2003-09-04
PL351842A1 (en) 2003-06-16
IL145134A (en) 2010-11-30
LU92159I2 (fr) 2013-04-29
TR200102715T2 (tr) 2002-09-23
TR200802278T2 (tr) 2008-08-21
PL218748B1 (pl) 2015-01-30
JP2002542770A (ja) 2002-12-17
AR063780A2 (es) 2009-02-18
IL207029A0 (en) 2010-12-30
CA2796140A1 (fr) 2000-09-28
BG106027A (bg) 2002-06-28
HUP0200575A2 (en) 2002-06-29
SI2168984T1 (sl) 2012-12-31
SK288082B6 (sk) 2013-06-03
AR043274A1 (es) 2005-07-27
EP2301970A1 (fr) 2011-03-30
EP2319870A2 (fr) 2011-05-11
CY1113326T1 (el) 2016-06-22
NO334828B1 (no) 2014-06-10
WO2000056772A1 (fr) 2000-09-28
KR20020026416A (ko) 2002-04-10
BR0009323A (pt) 2002-01-08
KR20060127247A (ko) 2006-12-11
SK13672001A3 (sk) 2002-03-05
NZ529571A (en) 2006-03-31
CA2365281C (fr) 2009-08-04
NZ611563A (en) 2015-01-30
JP2014138594A (ja) 2014-07-31
KR100818066B1 (ko) 2008-03-31
EP2319870A3 (fr) 2011-10-26
NO20131482L (no) 2001-11-26
KR20130105766A (ko) 2013-09-25
JP4841038B2 (ja) 2011-12-21
EP2168984B1 (fr) 2012-08-29
NO20014605D0 (no) 2001-09-21
KR101222450B1 (ko) 2013-01-16
AU3921600A (en) 2000-10-09
NZ592550A (en) 2012-12-21
NZ596723A (en) 2013-07-26
CN101921772A (zh) 2010-12-22
CA2669512A1 (fr) 2000-09-28
CN1351614A (zh) 2002-05-29
NO2014024I1 (no) 2014-09-18
IL145134A0 (en) 2002-06-30
PL409839A1 (pl) 2015-03-30
CN100439399C (zh) 2008-12-03
NO20014605L (no) 2001-11-26
TW201215619A (en) 2012-04-16
CN101921772B (zh) 2013-03-27
MY145191A (en) 2011-12-30
CN101066997A (zh) 2007-11-07
PT2168984E (pt) 2012-09-24
CZ20013434A3 (cs) 2002-08-14
CY2013007I1 (el) 2020-05-29
DK2168984T3 (da) 2012-12-10
HUP0200575A3 (en) 2004-11-29
BG111337A (bg) 2013-02-28
JP2012010702A (ja) 2012-01-19
CA2365281A1 (fr) 2000-09-28
MY142984A (en) 2011-02-14
CZ303725B6 (cs) 2013-04-03
TWI410433B (zh) 2013-10-01
TR200501367T2 (tr) 2005-09-21

Similar Documents

Publication Publication Date Title
TWI365193B (en) Human antibodies that bind human il-12 and methods for producing
PT1818343E (pt) Anticorpos contra a il-12 humana
ZA200206266B (en) Antibodies that bind human interleukin-18 and methods of making and using.
IL149907A0 (en) Nutritional composition, methods of producing said composition and methods of using said composition
PL363322A1 (en) Combination therapy using anti-egfr antibodies and anti-hormonal agents
AU6266899A (en) Methods for producing human tumor antigen specific antibodies
IL201751A (en) Compounds that bind il-17-like cytokine and antibodies
IL149029A0 (en) High mannose proteins and methods for producing the same
ZA9810130B (en) Tumor-specific antigens methods for their production and their use for imunization and diagnosis
AU2002227369A1 (en) Methods for producing and purifying recombinant alpha-l-iduronidase
AU7676300A (en) Human anti-adipocyte monoclonal antibodies and their use
IL153539A0 (en) Protein complexes and methods for the preparation thereof
AU5441000A (en) Human monoclonal antibody
HK1040421A1 (en) Ornament and method for preparation thereof
HK1043921B (zh) 裝飾用墊片及其製造方法
IL141523A0 (en) High-affinity antibodies
HUP0105166A3 (en) Substances wk-5344a and wk-5344b and process for producing the same
EP1350847A4 (fr) Antigene de gliomes humains et procede de preparation de cet antigene
GB9923117D0 (en) Insect-paper and methods for its formation and use
HU9903394D0 (en) Net-jewel and method for producing it
IL148165A0 (en) Therapeutic antibody against muc-1 antigen and methods for their use
AU1033401A (en) Novel limonoids for use particularly in the treatment of cancer and method for producing the same
GB0017139D0 (en) Human monoclonal antibodies
GB0016824D0 (en) Human monoclonal antibodies
GB9927698D0 (en) Therapeutic antibody

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170324